CN104872677A - Dietary composition for benefiting planting and multiplication of probiotics in host body and application thereof - Google Patents
Dietary composition for benefiting planting and multiplication of probiotics in host body and application thereof Download PDFInfo
- Publication number
- CN104872677A CN104872677A CN201510341016.3A CN201510341016A CN104872677A CN 104872677 A CN104872677 A CN 104872677A CN 201510341016 A CN201510341016 A CN 201510341016A CN 104872677 A CN104872677 A CN 104872677A
- Authority
- CN
- China
- Prior art keywords
- dietary composition
- probio
- active peptide
- metabolic syndrome
- dietary fiber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000007882 dietary composition Nutrition 0.000 title claims abstract description 17
- 239000006041 probiotic Substances 0.000 title abstract description 6
- 235000018291 probiotics Nutrition 0.000 title abstract description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 36
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 33
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 23
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 23
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 150000004676 glycans Chemical class 0.000 claims description 15
- 229920001282 polysaccharide Polymers 0.000 claims description 15
- 239000005017 polysaccharide Substances 0.000 claims description 15
- 241000218231 Moraceae Species 0.000 claims description 10
- 235000008708 Morus alba Nutrition 0.000 claims description 10
- 241000186000 Bifidobacterium Species 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 102000008186 Collagen Human genes 0.000 claims description 7
- 108010035532 Collagen Proteins 0.000 claims description 7
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 7
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 7
- 229920001436 collagen Polymers 0.000 claims description 7
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 7
- 229920000377 Sinistrin Polymers 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 241000186012 Bifidobacterium breve Species 0.000 claims description 5
- 244000068988 Glycine max Species 0.000 claims description 5
- 235000010469 Glycine max Nutrition 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 5
- 239000000835 fiber Substances 0.000 claims description 5
- 230000000153 supplemental effect Effects 0.000 claims description 5
- 241001468229 Bifidobacterium thermophilum Species 0.000 claims description 4
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 4
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 4
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 4
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 4
- 244000199866 Lactobacillus casei Species 0.000 claims description 4
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 4
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 4
- 102000014171 Milk Proteins Human genes 0.000 claims description 4
- 108010011756 Milk Proteins Proteins 0.000 claims description 4
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 4
- 229940017800 lactobacillus casei Drugs 0.000 claims description 4
- 235000021239 milk protein Nutrition 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 241001608472 Bifidobacterium longum Species 0.000 claims description 3
- 241000194032 Enterococcus faecalis Species 0.000 claims description 3
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 3
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 3
- 241000209140 Triticum Species 0.000 claims description 3
- 235000021307 Triticum Nutrition 0.000 claims description 3
- 240000008042 Zea mays Species 0.000 claims description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 3
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 3
- 235000005822 corn Nutrition 0.000 claims description 3
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 15
- 235000012000 cholesterol Nutrition 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 6
- 208000004930 Fatty Liver Diseases 0.000 abstract description 5
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 5
- 208000010706 fatty liver disease Diseases 0.000 abstract description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 5
- 230000002503 metabolic effect Effects 0.000 abstract description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 2
- 239000000843 powder Substances 0.000 description 22
- 239000008280 blood Substances 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- 230000007423 decrease Effects 0.000 description 10
- 230000006872 improvement Effects 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- 230000036186 satiety Effects 0.000 description 7
- 235000019627 satiety Nutrition 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 235000021196 dietary intervention Nutrition 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 235000012631 food intake Nutrition 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 208000017667 Chronic Disease Diseases 0.000 description 4
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 208000004611 Abdominal Obesity Diseases 0.000 description 3
- 206010065941 Central obesity Diseases 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 241000305071 Enterobacterales Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 231100000284 endotoxic Toxicity 0.000 description 2
- 230000002346 endotoxic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000001022 morbid obesity Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000276438 Gadus morhua Species 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241001561398 Lactobacillus jensenii Species 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000276701 Oreochromis mossambicus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000010501 heavy metal poisoning Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000021083 high saturated fats Nutrition 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920000344 molecularly imprinted polymer Polymers 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/123—Bulgaricus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/225—Faecalis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/231—Lactis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/249—Thermophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/537—Thermacidophilum
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides a dietary composition for benefiting planting and multiplication of probiotics in a host body. The dietary composition is prepared by the following raw materials in part by weight: 0.05-2% of probiotics, 50-70% of soluble dietary fiber and 28-49.95% of biological active peptide. The invention further provides an application of the dietary composition in assistant treatment of metabolic syndrome. Through the mixture of the probiotics, soluble dietary fiber and biological active peptide, the metabolic syndrome patient can rebuild up a health flora, promote the flora to multiply and grow, and remove harmful matters in the body; after taking for a period of time, the metabolic syndrome patient loses weight, keeps glucostasis; moreover, triglyceride and total cholesterol are reduced, the fatty liver is obviously improved; and thereby, every metabolic index of the human body is gradually recovered to normal.
Description
Technical field
The invention belongs to field of food, relate to a kind of Combined food composition formula, particularly relate to and a kind ofly contribute to the dietary composition of probio in host's field planting and propagation, and the application in supplemental treatment metabolic syndrome.
Background technology
The syndrome that metabolic syndrome is is feature with hyperglycaemia, hypertension, high fat of blood and overweight, its most important feature is central obesity and insulin resistance.Metabolic syndrome is the high-risk risk factor of a lot of chronic disease as diabetes, coronary heart disease, headstroke and all kinds of cancers etc.
[1].On the surface, all kinds of chronic disease has pathogenesis and the pathological change of " different separately "; From essential analysis, they are actually the same thing, suffer from wherein a kind of disease patient, and the risk suffering from other diseases can increase several times.Research clearly, metabolic syndrome institute with each risk factor have and independently act on, combine the effect then producing and work in coordination with amplification
[1,2].Therefore, the nutritional prevention of chronic disease is an entirety, the thinking inertia such as simple " hypoglycemic ", " step-down ", " lipopenicillinase " of necessary beyond tradition, and various information summary should be considered and take corresponding measure.Bad life style, particularly the incorrect eating habit such as " high-energy, high saturated fat, high cholesterol, high sugar, high purine " causes the illness that metabolic syndrome appears in human body, and therefore reasonable diet plays the part of very important role in the control of metabolic syndrome
[3].
At present, for metabolic syndrome control mainly by medicine and change dietary structure.For a long time, owing to achieving no breakthrough to the study on the genesis of metabolic syndrome, can only take stopgap measures by medicine control metabolic syndrome and not effect a permanent cure, although the symptom of improving, but, lysis does not block, and most of patients still develops into different chronic diseases, and the complication caused therefrom does not also obviously reduce.And Most patients changes the measure of dietary structure because can not be adhered to for a long time and produce little effect
[1,2].Recent research display metabolic syndrome may be lacked of proper care relevant with gastrointestinal bacterial flora, the probio quantity such as the crowd Bifidobacterium of metabolic syndrome decline, and enterobacteria and proteus etc. produce the increase of endotoxic saprophytic bacteria quantity, supplement or regulate probio value volume and range of product then to contribute to improving metabolic syndrome
[3].
Probio is the active microorganism that a class is useful to host, is to be colonizated in human body intestinal canal, reproductive system, can produce definite health efficacy thus improve host's microecological balance, plays the active beneficial microorganism general name of beneficial effect.Confirm after deliberation, the probios such as Bifidobacterium significantly can reduce serum cholesterol and triglyceride content, have reducing blood lipid, hypoglycemic, hypotensive and prevention Cardial or cerebral vascular diseases effect
[4,5].Probio obviously can increase content and the biologically active thereof of superoxide dismutase in body, super oxyradical generation disproportionation, closed and degraded in effective promotion body, accelerate the removing of interior free yl, thus increase the oxidation resistance of body, prevent and treat the generation of metabolic syndrome, delay body aging
[3].
Dietary fiber refers to that can resist human small intestine digests and assimilates, and the summation of edible vegetable ingredients, carbohydrate and the similar substance thereof that can partly or entirely ferment at human body large intestine.Dietary fiber is different according to dissolubility, be divided into soluble dietary fiber and the large class of insoluble diedairy fiber two, soluble dietary fiber dissolves in warm water or hot water, and its aqueous solution can by the ethanol of 4 times 95% reppd part fiber, mainly comprise polysaccharide string
[6].Soluble dietary fiber Absorbable rod is equivalent to self tuple water doubly, and imbibition in stomach and intestine also forms full-bodied colloidal sol or gel, makes people produce satiety and suppresses feed.Have obese people and regulate effect of weight reducing preferably.The organic molecules such as dietary fiber energy absorption of bile acid, cholesterol mutagen, suppress total cholesterol concentration to raise, and reduce synthesis and the absorption of cholic acid and its esters, reduce human plasma and hepatic cholesterol level, angiocardiopathy preventing.Soluble dietary fiber can also adsorb glucose makes absorption slow down
[6].Soluble dietary fiber also has the effect of a kind of glucagon suppression secretion in addition, so just can give full play to the effect of insulin, prevent and treat diabetes
[7].In addition, soluble dietary fiber also has the effect of absorption human free radical.Soluble dietary fiber can exchange with the heavy metal ion such as copper, lead, alleviates heavy metal poisoning.The more important thing is that it can exchange with K+, the Na+ in enteron aisle, impel in urine and ight soil and discharge Na, K in a large number, thus reduce Na+ and the K+ ratio in blood, produce the effect reduced blood pressure.Soluble dietary fiber can delay gastric emptying, forms a kind of mucous membrane in stomach, and the process of digesting and assimilating of dietary nutrient is slowed down.Like this, the sugar in blood can only slowly increase, or insulin slightly deficiency also unlikely horse back cause blood sugar concentration to increase, blood sugar in diabetic patients level can be reduced.What is more important, after soluble dietary fiber is taken, the growth of the beneficial bacterium such as intestinal bifidobacteria, Bacillus acidi lactici can be promoted, suppress enterobacteria etc. to produce the breeding of endotoxic harmful bacteria, produce a large amount of SCFA simultaneously, add acetic acid, acetic acid, folic acid and lactic acid, change gut pH, improve the breeding environment of probio, thus accelerate intestines peristalsis, stool is discharged smoothly, and cholesterol, adjusting blood lipid, blood sugar, uric acid level can be reduced
[5,6].
Biologically active peptide refers to useful to the vital movement of living organism or has the peptides of physiological action, also known as Functional Polypeptides.These biologically active peptides are the Molecularly Imprinted Polymers between amino acid and protein, little of being made up of two amino acid, large to being formed by connecting by peptide bond by dozens of amino acid.Molecular weight is less than 6000D mostly, and complicated structure is various, and often derives through glycosylation, phosphorylation or acidylate, and the adjustment of cell physiological and metabolic function has important effect
[8].Biologically active peptide not only has easy to digest, easy absorption, promotes energetic supersession, anti-obesity, strengthen body immunity, reduce blood pressure and the various functions such as blood fat, prevention diseases of cardiovascular and cerebrovascular systems, and has the effect etc. of the proliferation of probiotics such as anti-ageing, antifatigue, promotion Bifidobacterium and lactic acid bacteria
[9], functional food and peptide pharmaceutical products can be prepared at Clinical practice.
But, short proliferation of probiotics effect now for soluble dietary fiber and biologically active peptide is only limitted to laboratory stage, by adding propagation quantity and the media environment pH value of measuring probio in soluble dietary fiber or biologically active peptide to culture medium, then situation is more complicated in human body environment for practical function, simply can not infer that its effect is consistent with laboratory.The minority clinical application research carried out at present is also only for one wherein, and therapeutic evaluation differs, and cannot provide total solution.
Summary of the invention
In order to solve the problem, play the clinical efficacy of above-mentioned meals class material better, by having carried out ingenious combination to different category, meticulous adjustment being carried out to ratio and emphasis is strictly regulated eating method, having achieved good clinical therapeutic efficacy.
The object of the present invention is to provide a kind of dietary composition contributing to probio field planting and propagation in host, thus have function of stabilizing body blood sugar after meal, adjusting blood lipid, adjustment blood pressure, adults person body weight, reduce the effect of uric acid content in blood and urine.
Object of the present invention can be achieved through the following technical solutions:
The invention provides a kind of dietary composition contributing to probio field planting and propagation in host, raw material comprising following weight fraction is prepared from, probio is 0.05% ~ 2%, soluble dietary fiber 50% ~ 70%, biologically active peptide 28% ~ 49.95%.
For better completing goal of the invention, described probio is selected from 1) lactobacillus class (lactobacillus acidophilus, Lactobacillus casei, Lactobacillus Jensenii, lactobacillus bulgaricus, Lactobacillus rhamnosus); 2) Bifidobacterium class (bifidobacterium longum, bifidobacterium breve, avette Bifidobacterium, bifidobacterium thermophilum); 3) two or more combinations in gram-positive cocci (streptococcus fecalis, galactococcus, streptococcus thermophilus).
Wherein the selection of probio adjusts according to host intestine flora situation with carrying out kind and ratio, beneficial bacteria of intestinal tract group lazy weight based on the probio of supplemental amount in body, the probio to adjust flora environment of gut flora field planting environment difference in body, what the two had concurrently then carries out corresponding collocation, in group, multiple probio is 1 part with the parts by weight of the minimum probio of consumption, then the parts by weight of the probio that consumption is the highest are: 1 part≤probio (high consumption)≤2 parts; If the probio kind used is more than two kinds, then all the other probio consumption proportions are in and are therebetween: probio (low consumption)≤probio (medium consumption)≤probio (high consumption).
For better completing goal of the invention, described soluble dietary fiber is plant polyose fiber element, is preferably two or more in polyfructosan, mulberries polysaccharide, LBP-X, Blackfungus polyhexose, Chinese yam polysaccharide, coixan.
Wherein soluble dietary fiber selection adjust according to host's symptom, do not accompany metabolic disease symptom (simple obesity) with nourishing, it is main for reducing triglycerides, with hyperglycaemia, high fat of blood, hypertension symptom be adjusted to the soluble dietary fiber kind with corresponding effect, if simultaneously with multiple symptom, select the soluble dietary fiber kind of many effects or variety classes combined, and according to severity of symptom adjustment proportion relation, in group, the content of multiple soluble dietary fiber is 1 part with the parts by weight of the minimum soluble dietary fiber of consumption, then the weight portion of the soluble dietary fiber that consumption is the highest is: 1 part≤soluble dietary fiber (high consumption)≤3 parts, if the soluble dietary fiber kind used is more than two kinds, then all the other soluble dietary fiber consumption proportions are in therebetween, for soluble dietary fiber (low consumption)≤soluble dietary fiber (medium consumption)≤soluble dietary fiber (high consumption).
For better completing goal of the invention, described biologically active peptide is soya-bean polypeptides, milk protein active peptide, wheat germ active peptide, corn protein peptide, Bone gillg or marine organisms collagen peptide.
Wherein marine organisms collagen peptide is extract in fish-skin from marine fishes (as salmon, dog salmon, cod, Tilapia mossambica etc.) to obtain.Select different activities peptide in different formulations mainly according to the merging symptom of host, in general, select Bone gillg with osteoporosis person; With high fat of blood, person selects milk protein active peptide; Companion's glycosuria patient selects marine organisms collagen peptide; Accompanied with hypertension person selects wheat germ active peptide; Companion's uric acid and the high selection corn protein peptide of cholesterol; Person selects soya-bean polypeptides not accompany metabolic disease.
Further, described host behaves.
The present invention also provides above-mentioned dietary composition as the application of the food of supplemental treatment metabolic syndrome.
Composition of the present invention can be made and reconstitute agent, reconstitutes with warm water, drinks on an empty stomach, every day three times, each 10 grams ~ 15 grams.Drink rear patient can gradually reduce the staple foods such as meat, eggs and milk rice and flour intake according to oneself satiety situation, increase the intake of the plant foods such as vegetable and fruit, accomplish often to eat not starve and do not eat, be hungry and just eat.
Wherein each component in probio
The representative dosage period of the present composition be January to some months, after the every metabolic index of human body is normal gradually, can progressively decrement, until stop.Also can discontinuity long-term taking.
Beneficial effect of the present invention is:
The invention provides a kind of dietary composition of supplemental treatment metabolic syndrome, it is by the proportioning of probio, soluble dietary fiber and biologically active peptide, make the patient suffering from metabolic syndrome can rebuild healthy flora, and promote flora proliferate, get rid of harmful substance in body, through taking after a while, the weight in patients suffering from metabolic syndrome is reduced, glucostasis, triglycerides and T-CHOL decline, fatty liver has clear improvement, thus makes the every metabolic index of human body recover normal gradually.
Detailed description of the invention
Below employing embodiment illustrates the special diet composition and method of making the same that the present invention is applicable to metabolic syndrome crowd:
Embodiment 1
Measurement unit is weight percentage
Bifidobacterium longum 0.05%, bifidobacterium breve 0.08%, mulberries polysaccharide 50%, LBP-X 20%, soya-bean polypeptides 29.87%.
Each raw material is taken (on sale on market by formula, all made and be less than 100 object fine powders) first by mulberries polysaccharide powder, LBP-X powder and soyabean polypeptide powder routine mixing after bifidobacteria viable bacteria freeze-dried powder is mixed rapidly after, be placed in 4 degree of refrigerator cold-storages immediately for subsequent use.
Instructions of taking: reconstitute with warm water (40 DEG C) 150ml, drinks, every day three times, each 10 grams ~ 15 grams on an empty stomach.Drink rear patient can gradually reduce staple food intake according to oneself satiety situation, accomplish that maximum 6 points of each dining is satisfied, do not starve and do not eat.
Nutritional intervention is carried out to severe obeisity volunteer in 26, and health body weight in intervention and body mass index (BMI) are monitored, further describe the present invention.Experimental result shows after all volunteers intervene January, February, April, and body weight and BMI continue significantly to decline, and the average weight decline 2.4kg/ month, have 17 people (65.38%) to recover SBW after April, BMI on average declines 1.8/ month.
Embodiment 2
Measurement unit is weight percentage
Bifidobacterium thermophilum 0.05%, streptococcus thermophilus 0.05%, lactobacillus acidophilus 0.1%, mulberries polysaccharide 40%, Chinese yam polysaccharide 20%, marine organisms collagen peptide 39.8%.
Each raw material is taken (on sale on market by formula, all make and be less than 100 object fine powders) first by after the mixing of mulberries polysaccharide powder, Chinese yam polysaccharide powder and marine organisms collagen Gly-His-Lys routine, long bifidobacterium thermophilum, streptococcus thermophilus and live lactobacillus acidophilus freeze-dried powder are mixed rapidly, be placed in 4 degree of refrigerator cold-storages immediately for subsequent use.
Instructions of taking: reconstitute with warm water (40 DEG C) 150ml, drinks, every day three times, each 10 grams ~ 15 grams on an empty stomach.Drink rear patient can gradually reduce staple food intake according to oneself satiety situation, accomplish that maximum 6 points of each dining is satisfied, do not starve and do not eat.
Carry out nutritional intervention to the volunteer of 15 central obesity disease companion diabetes, experimental result shows all volunteer's glycometabolisms and all has clear improvement.Compared with every physiological and biochemical index of intervening first 1 week with volunteer, after intervening January, February, April, body weight and BMI continue significantly to decline, fasting blood-glucose, FPI reduce, the improvement of the sugared stable situation of direct reflection, simultaneously fatty liver (volunteer have 90% intervention after situation take a turn for the better, wherein 30% intervene after transfer to normal).
Embodiment 3
Measurement unit is weight percentage
Lactobacillus rhamnosus 0.05%, galactococcus 0.05%, lactobacillus acidophilus 0.1%, mulberries polysaccharide 30%, Blackfungus polyhexose 20%, milk protein active peptide 49.8%.
Each raw material is taken (on sale on market by formula, all make and be less than 100 object fine powders) first by after the mixing of mulberries polysaccharide powder, Blackfungus polyhexose powder and marine organisms collagen Gly-His-Lys routine, Lactobacillus rhamnosus, galactococcus and live lactobacillus acidophilus freeze-dried powder are mixed rapidly, be placed in 4 degree of refrigerator cold-storages immediately for subsequent use.
Instructions of taking: reconstitute with warm water (40 DEG C) 150ml, drinks, every day three times, each 10 grams ~ 15 grams on an empty stomach.Drink rear patient can gradually reduce staple food intake according to oneself satiety situation, accomplish that maximum 6 points of each dining is satisfied, do not starve and do not eat.
Carry out nutritional intervention to the volunteer of severe obesity companion high fat of blood in 12, experimental result display to be intervened terminate rear all volunteer's body weight and blood lipids index all has clear improvement April.Compared with the indices of intervening first 1 week with volunteer, after intervening January, February, April, weight in patients and BMI continue significantly to decline, triglycerides on average declines 0.68mmol/L, T-CHOL on average declines 0.52mmol/L, simultaneously fatty liver (volunteer have 90% intervention after situation take a turn for the better, wherein 30% intervene after transfer to normal) situation has clear improvement.
Embodiment 4
Measurement unit is weight percentage
Streptococcus fecalis 0.1%, lactobacillus bulgaricus 0.1%, polyfructosan 50%, coixan 20%, Bone gillg 29.8%.
Each raw material is taken (on sale on market by formula, all make and be less than 100 object fine powders) first by after the mixing of polyfructosan powder, coixan powder and ossein Gly-His-Lys routine, galactococcus and lactobacillus acidophilus freeze-drying powder are mixed rapidly, be placed in 4 degree of refrigerator cold-storages immediately for subsequent use.
Instructions of taking: reconstitute with warm water (40 DEG C) 150ml, drinks, every day three times, each 10 grams ~ 15 grams on an empty stomach.Drink rear patient can gradually reduce staple food intake according to oneself satiety situation, accomplish that maximum 6 points of each dining is satisfied, do not starve and do not eat.
Carry out nutritional intervention to 17 central obesity disease companion's diabetes and hypertensive volunteer, experimental result display intervention in April terminates rear all volunteer's glycometabolisms and blood markers all has clear improvement.Compared with every physiological and biochemical index of intervening first 1 week with volunteer, after intervening January, February, April, weight in patients and BMI continue significantly to decline, and on average decline 2.2mmol/L, on an empty stomach pancreas islet of fasting blood-glucose on average reduces by 1.6 μ IU/ml, and blood pressure on average declines 21mmHg simultaneously.
Embodiment 5
Measurement unit is weight percentage
Bifidobacterium breve 0.05%, galactococcus 0.05%, Lactobacillus casei 0.1%, polyfructosan 30%, mulberries polysaccharide 30%, coixan 10%, Bone gillg 29.8%.
Each raw material is taken (on sale on market by formula, all make and be less than 100 object fine powders) first by after the mixing of polyfructosan powder, mulberries polysaccharide powder, coixan powder and ossein Gly-His-Lys routine, bifidobacterium breve, galactococcus and Lactobacillus casei viable bacteria freeze-dried powder are mixed rapidly in proportion, be placed in 4 degree of refrigerator cold-storages immediately for subsequent use.
Instructions of taking: reconstitute with warm water (40 DEG C), drinks, every day three times, each 10 grams ~ 15 grams on an empty stomach.Drink rear patient can gradually reduce staple food intake according to oneself satiety situation, accomplish that maximum 6 points of each dining is satisfied, do not starve and do not eat.
Nutritional intervention is carried out to severe obesity companion hyperglycaemia in various degree, hypertension, high fat of blood, high lithemia volunteer in 32, and the every physical signs of health in intervention is carried out to the monitoring of system, monitoring result in table 1, for intervening the physiological change of health and the Molecular Evaluation of intervention effect in overall process to volunteer.
Table 1: volunteer's nutritional intervention overall process physiological change index
Data are expressed as mean+SD.Paired t-test (normal distribution data) or nonparametric distribution Wilcoxon inspection (non-normal data) is adopted to be completed by the analysis of SPSS 19.0 statistical software.
After intervening, January, February compared * P < 0.05, * * P < 0.01 with before intervention 1 week, and after intervening, April compares # < 0.05 with January after intervention.
This experimental result display volunteer metabolism of glucose and lipid has clear improvement.Compared with every physiological and biochemical index of intervening first 1 week with volunteer, after intervening January, February, April, body weight and BMI continue significantly to decline, and fasting blood-glucose, FPI reduce, and directly reflect the improvement of sugared stable situation; The decline of triglycerides and T-CHOL shows the lipometabolic improvement of body; The obvious reduction of three kinds of transaminases illustrates that the damage of liver cell alleviates; Simultaneously fatty liver (volunteer have 76% intervention after situation take a turn for the better, wherein 15% intervene after transfer to normal) all make moderate progress with blood pressure.
Above specific embodiments of the invention are described.It is to be appreciated that the present invention is not limited to above-mentioned particular implementation, those skilled in the art can make various changes and modifications within the scope of the claims, and this does not affect flesh and blood of the present invention.
Bibliography:
1. health sea is quiet, Wang Hualiang.The progress of metabolic syndrome.Medical review, 2007,13 (1): 68-70
2. Wu Nan nanmu, Li Qiang.The Pathogenesis of metabolic syndrome.Harbin Medical University's journal, 2010,44 (1): 95-98
3. Luo Jia, Jiang Chunyan.The progress of intestinal microecology and metabolic disease relation.Gastroenterology, 2013,18 (9) 569-571
4. Hu Xingyun, Li Yan.Gut flora and diabetes B, drug assessment, 2013,10 (21) 8-11
5. permitted to build intelligent, Zou great Jin.Gut flora and obesity, drug assessment, 2013,10 (21) 15-18
6. Xu Xiao flies, Jiang Li, Tang Jian, Ma Zhonghua.The health care of plant polyose and DEVELOPMENT PROSPECT thereof, Chinese food and nutrition, 2007,12 (1) 45-50
7. Soviet Union's capital and interest.Intervene the therapy approach that can gut flora become diabetes, drug assessment, 2013,10 (21) 22-25
8. Wang Ying, Xu Xiulin, Zhu Naishuo.The progress of biologically active peptide function of blood sugar reduction.Food Science, 2012,33 (9) 341-344
9. Wang Zhu is clear, Li Bafang.Biologically active peptide and progress thereof.Chinese Journal of Marine Drugs, 2010,29 (2): 60-68.
Claims (7)
1. one kind contributes to the dietary composition of probio field planting and propagation in host, it is characterized in that, be prepared from by the raw material of following weight fraction, probio is 0.05% ~ 2%, soluble dietary fiber 50% ~ 70%, biologically active peptide 28% ~ 49.95%.
2. dietary composition as claimed in claim 1, it is characterized in that, described probio be selected from lactobacillus acidophilus, Lactobacillus casei, lactobacillus bulgaricus, Lactobacillus rhamnosus, bifidobacterium longum, bifidobacterium breve, avette Bifidobacterium, bifidobacterium thermophilum, streptococcus fecalis, galactococcus, streptococcus thermophilus two or more.
3. dietary composition as claimed in claim 1, is characterized in that, described soluble dietary fiber is plant polyose fiber element.
4. dietary composition as claimed in claim 3, is characterized in that, described plant polyose fiber element be selected from polyfructosan, mulberries polysaccharide, LBP-X, Blackfungus polyhexose, Chinese yam polysaccharide, coixan two or more.
5. dietary composition as claimed in claim 1, it is characterized in that, described biologically active peptide is selected from soya-bean polypeptides, milk protein active peptide, wheat germ active peptide, corn protein peptide, Bone gillg or marine organisms collagen peptide.
6. dietary composition as claimed in claim 1, is characterized in that, described host behaves.
7. the dietary composition as described in any one of claim 1-6 is as the application of the food of supplemental treatment metabolic syndrome.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510341016.3A CN104872677A (en) | 2015-06-18 | 2015-06-18 | Dietary composition for benefiting planting and multiplication of probiotics in host body and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510341016.3A CN104872677A (en) | 2015-06-18 | 2015-06-18 | Dietary composition for benefiting planting and multiplication of probiotics in host body and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104872677A true CN104872677A (en) | 2015-09-02 |
Family
ID=53940576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510341016.3A Pending CN104872677A (en) | 2015-06-18 | 2015-06-18 | Dietary composition for benefiting planting and multiplication of probiotics in host body and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104872677A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106173853A (en) * | 2016-07-15 | 2016-12-07 | 中国科学院南海海洋研究所 | The alimentation composition of a kind of blood fat reducing and application thereof |
| CN107836721A (en) * | 2017-12-11 | 2018-03-27 | 青岛四季康健生物科技有限公司 | A kind of composition with intestines and stomach healthcare function and preparation method thereof |
| CN109924505A (en) * | 2017-12-15 | 2019-06-25 | 上海海洋大学 | A kind of NEW TYPE OF COMPOSITE probiotic food |
| CN111642753A (en) * | 2020-07-17 | 2020-09-11 | 广州同康生物科技有限公司 | Dietary nutrition supplement composition and preparation method thereof |
| CN113749180A (en) * | 2021-11-09 | 2021-12-07 | 山东健源生物科技有限公司 | Biological compound preparation for improving organism immunity of pets and preparation method thereof |
| WO2022188335A1 (en) * | 2021-03-10 | 2022-09-15 | 中农宠物营养研究院(江苏)有限公司 | Chitosan-fe-coating-based synbiotic microcapsule capable of resisting gastric acid and realizing targeted release in intestinal tract, and preparation method therefor |
| US11688507B2 (en) | 2020-12-29 | 2023-06-27 | Kpn Innovations, Llc. | Systems and methods for generating a metabolic dysfunction nourishment program |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102511788A (en) * | 2011-11-21 | 2012-06-27 | 陈应交 | Probiotic viable bacterium particle and preparation method thereof |
| CN102551043A (en) * | 2011-10-29 | 2012-07-11 | 山东好当家海洋发展股份有限公司 | Oyster polypeptide nutrition supplement food for children and preparation method thereof |
| CN103549410A (en) * | 2013-09-24 | 2014-02-05 | 中国科学院南海海洋研究所 | Intestinal mucosa protection and restoration type enteral nutritive product and preparation method thereof |
-
2015
- 2015-06-18 CN CN201510341016.3A patent/CN104872677A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102551043A (en) * | 2011-10-29 | 2012-07-11 | 山东好当家海洋发展股份有限公司 | Oyster polypeptide nutrition supplement food for children and preparation method thereof |
| CN102511788A (en) * | 2011-11-21 | 2012-06-27 | 陈应交 | Probiotic viable bacterium particle and preparation method thereof |
| CN103549410A (en) * | 2013-09-24 | 2014-02-05 | 中国科学院南海海洋研究所 | Intestinal mucosa protection and restoration type enteral nutritive product and preparation method thereof |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106173853A (en) * | 2016-07-15 | 2016-12-07 | 中国科学院南海海洋研究所 | The alimentation composition of a kind of blood fat reducing and application thereof |
| CN106173853B (en) * | 2016-07-15 | 2020-05-19 | 中国科学院南海海洋研究所 | Nutritional composition for reducing blood fat and application thereof |
| CN107836721A (en) * | 2017-12-11 | 2018-03-27 | 青岛四季康健生物科技有限公司 | A kind of composition with intestines and stomach healthcare function and preparation method thereof |
| CN109924505A (en) * | 2017-12-15 | 2019-06-25 | 上海海洋大学 | A kind of NEW TYPE OF COMPOSITE probiotic food |
| CN111642753A (en) * | 2020-07-17 | 2020-09-11 | 广州同康生物科技有限公司 | Dietary nutrition supplement composition and preparation method thereof |
| US11688507B2 (en) | 2020-12-29 | 2023-06-27 | Kpn Innovations, Llc. | Systems and methods for generating a metabolic dysfunction nourishment program |
| WO2022188335A1 (en) * | 2021-03-10 | 2022-09-15 | 中农宠物营养研究院(江苏)有限公司 | Chitosan-fe-coating-based synbiotic microcapsule capable of resisting gastric acid and realizing targeted release in intestinal tract, and preparation method therefor |
| CN113749180A (en) * | 2021-11-09 | 2021-12-07 | 山东健源生物科技有限公司 | Biological compound preparation for improving organism immunity of pets and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104872677A (en) | Dietary composition for benefiting planting and multiplication of probiotics in host body and application thereof | |
| CN104519895B (en) | The therapeutical uses of Chardonnay seed products | |
| ES2702977T3 (en) | Bifidobacteria for the treatment of diabetes and related conditions | |
| CN107106584A (en) | Synthetic composition for treating dysbolism | |
| CN107692240A (en) | A kind of high protein diet composition and its preparation method and application | |
| TW200918082A (en) | Supplementation of maternal diet | |
| CN106174585A (en) | Hypoglycemic compositions and hypoglycemic compound probiotic spy's dietary seafood | |
| CN100577036C (en) | Use of pullulan as a slowly digested carbohydrate | |
| CN105792673A (en) | Use of nutritional compositions having a low protein amount | |
| BRPI0707336A2 (en) | use of probiotic microorganisms for the treatment and prevention of obesity and related disorders | |
| AU2004277417A1 (en) | Compositions and methods for augmenting kidney function | |
| CN110338402A (en) | A kind of compound probiotic powder and preparation method thereof | |
| CN107950851A (en) | One kind is without bitter taste complex polypeptide powder | |
| CN104187708A (en) | Total-nutrient formulated food for patients with diabetes | |
| BRPI1010617B1 (en) | use of a composition, composition, and method for preparing a composition | |
| CN109481510A (en) | It is a kind of to help to improve diabetes B and its synbiotic compound preparation of complication and preparation method thereof | |
| JP5592640B2 (en) | Antistress agent containing lactic acid bacteria fermented royal jelly, method for producing the same, hypothalamus-pituitary-adrenocortical activity inhibitor, and sympathetic-adrenal medullary activity inhibitor | |
| CN106690331A (en) | Kelp dietary fiber granules and preparation method thereof | |
| CN102113652A (en) | Special dietary extruded rice applicable to patients suffering from 'five-high' metabolic syndrome and preparation method thereof | |
| CN102283342B (en) | Functional total-nutrient liquid food for space flight and preparation method thereof | |
| CN111543605A (en) | Comprehensive nutrition powder for people with hypertension, hyperlipidemia and obesity | |
| CN105661547A (en) | Probiotics and Bombyx mori compounded diabetic patient nutritional supplement | |
| JP2013538827A (en) | Compositions and methods for enhancing renal function | |
| WO2012142678A1 (en) | Weight loss composition | |
| CN108523123A (en) | A kind of full nutritional support food of diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150902 |